Bank of New York Mellon Corp increased its position in Sarepta Therapeutics Inc (NASDAQ:SRPT) by 22.3% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 315,803 shares of the biotechnology company’s stock after buying an additional 57,592 shares during the quarter. Bank of New York Mellon Corp owned 0.49% of Sarepta Therapeutics worth $14,323,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also recently added to or reduced their stakes in SRPT. Ameritas Investment Partners Inc. lifted its position in Sarepta Therapeutics by 6.3% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 4,561 shares of the biotechnology company’s stock worth $154,000 after buying an additional 271 shares during the last quarter. Cubist Systematic Strategies LLC lifted its position in Sarepta Therapeutics by 116.4% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 4,600 shares of the biotechnology company’s stock worth $155,000 after buying an additional 2,474 shares during the last quarter. Fox Run Management L.L.C. bought a new stake in Sarepta Therapeutics in the 3rd quarter worth approximately $204,000. Bayesian Capital Management LP bought a new stake in Sarepta Therapeutics in the 2nd quarter worth approximately $206,000. Finally, Strs Ohio bought a new stake in Sarepta Therapeutics in the 3rd quarter worth approximately $208,000. Institutional investors own 82.02% of the company’s stock.

Sarepta Therapeutics Inc (SRPT) opened at $55.05 on Thursday. The company has a current ratio of 10.44, a quick ratio of 9.52 and a debt-to-equity ratio of 0.04. Sarepta Therapeutics Inc has a 12 month low of $26.26 and a 12 month high of $57.57.

Sarepta Therapeutics (NASDAQ:SRPT) last posted its earnings results on Wednesday, October 25th. The biotechnology company reported ($0.20) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.86) by $0.66. Sarepta Therapeutics had a negative return on equity of 51.72% and a negative net margin of 112.08%. The firm had revenue of $45.95 million for the quarter, compared to analysts’ expectations of $41.29 million. During the same period in the previous year, the firm earned ($0.95) earnings per share. analysts predict that Sarepta Therapeutics Inc will post -3.11 earnings per share for the current year.

In other news, Director Hans Lennart Rudolf Wigzell sold 6,667 shares of the business’s stock in a transaction that occurred on Thursday, November 30th. The stock was sold at an average price of $55.89, for a total transaction of $372,618.63. Following the transaction, the director now directly owns 13,333 shares of the company’s stock, valued at $745,181.37. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Douglas S. Ingram bought 38,138 shares of Sarepta Therapeutics stock in a transaction dated Wednesday, November 8th. The shares were acquired at an average cost of $52.44 per share, for a total transaction of $1,999,956.72. Following the completion of the purchase, the chief executive officer now directly owns 420,196 shares of the company’s stock, valued at approximately $22,035,078.24. The disclosure for this purchase can be found here. Insiders have sold 28,167 shares of company stock worth $1,497,619 over the last three months. Insiders own 9.60% of the company’s stock.

SRPT has been the subject of a number of recent research reports. Goldman Sachs Group restated a “buy” rating and issued a $71.00 target price on shares of Sarepta Therapeutics in a research report on Friday, October 6th. ValuEngine downgraded Sarepta Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, October 2nd. Oppenheimer reaffirmed a “buy” rating on shares of Sarepta Therapeutics in a research note on Monday, September 25th. SunTrust Banks reaffirmed a “buy” rating and issued a $56.00 price target on shares of Sarepta Therapeutics in a research note on Thursday, September 7th. Finally, Robert W. Baird reaffirmed a “buy” rating and issued a $101.00 price target on shares of Sarepta Therapeutics in a research note on Tuesday, October 17th. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating and sixteen have issued a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $64.14.

COPYRIGHT VIOLATION NOTICE: “Bank of New York Mellon Corp Purchases 57,592 Shares of Sarepta Therapeutics Inc (SRPT)” was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this article on another publication, it was copied illegally and republished in violation of U.S. and international copyright and trademark legislation. The legal version of this article can be viewed at https://www.thecerbatgem.com/2017/12/21/bank-of-new-york-mellon-corp-purchases-57592-shares-of-sarepta-therapeutics-inc-srpt.html.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).

Want to see what other hedge funds are holding SRPT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sarepta Therapeutics Inc (NASDAQ:SRPT).

Institutional Ownership by Quarter for Sarepta Therapeutics (NASDAQ:SRPT)

Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.